Zinc-[gamma]-pga compositions and methods for treating cancer

Abstract

The invention relates to pharmaceutical compositions comprising a zinc2+ salt and a γ-polyglutamic acid carrier, and, optionally, an NF-κB inhibitor as a tumor-sensitizing agent, and methods for using such compositions to treat tumors in patients. Methods include administering a liquid dosage form or a solid dosage form of a therapeutically effective amount of a Zn(II) salt and a γ-polyglutamic acid carrier to a patient in need thereof. Methods of treating a broad spectrum of human tumors, including tumors with a drug-resistant phenotype, using the disclosed compositions are provided. Tumors that respond to the pharmaceutical compositions disclosed herein include neuroendocrine (neuroblastoma), gastric, uterine, and lung tumors.

Dependencies are inferred from the claim text.